Analyst in order of appearance: Roth, Jefferies, UBS, Oppenheimer (Kevin DeJetter)sp.
Other than new developement of proprietary products and the increased research I have to perform in order to understand what they mean, I learned a few items I was interested in.
(1) $3.5 million royalty received from Baxter in January. This leaves $5.5 million due January, 09.
(2) Roche appears to still be in study, pre-clinical phase. Roche and Baxter are ramping up developement.
(3) Halozyme is very selective and has strict criteria for potential Enhanze partners. Two full time employees dedicated to Enhanze partners. If a deal is made, it will be a big one with a market leader. Still in discussions with potential partners.
(4) Next proprietary Enhanze product has multi-billion $ market and IND this year if memory serves. Need to listen again when time permits.
(5) Cellulite is a target along with others for dermatology. One of the more scientific contributors to the old board brought this up many months ago and could be over a year. Hope those very knowledgeable posters who seldom post, find their way to this board. Talk about understanding and foresight.
IMO, a very good call for long term investors, not exciting for speculators. While I am not happy with current sp, my long term outlook keeps getting better.
Jefferies report peged 2008 expenses right at $45 million so guidance from company of $40-50 million is no surprise. If Jeff is as accurate in balance of financial forcast, we are in great shape and will have $40-50 million cash remaining when cash flow positive in 2010.
Good Luck,
Rod
News 
Market Data 
Discover 
